ArticleGenome medicine2020
Network-based approaches elucidate differences within APOBEC and clock-like signatures in breast cancer.
Article in Genome medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Combined inference of known and novel mutational signatures with ReDeNovo.bioRxiv : the preprint server for biology · 2026Article
- Genomic spectra of lymphovascular invasion in breast cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Pan-cancer analysis of the interplay between mutational signatures and cellular signaling.iScience · 2024Article
- Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma.Cancers · 2023Article
- Cancer driver mutations: predictions and reality.Trends in molecular medicine · 2023Review
- Deficiency in mammalian STN1 promotes colon cancer development via inhibiting DNA repair.Science advances · 2023Article
- Influence network model uncovers relations between biological processes and mutational signatures.Genome medicine · 2023Article
- Identification of multiplicatively acting modulatory mutational signatures in cancer.BMC bioinformatics · 2022Article
- Mutational Signatures as Sensors of Environmental Exposures: Analysis of Smoking-Induced Lung Tissue Remodeling.Biomolecules · 2022Article
- An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.Cancer science · 2022Article
- RepairSig: Deconvolution of DNA damage and repair contributions to the mutational landscape of cancer.Cell systems · 2021Article
- A data-driven approach for constructing mutation categories for mutational signature analysis.PLoS computational biology · 2021Article
- Mutational Signatures: From Methods to Mechanisms.Annual review of biomedical data science · 2021Article
- The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.NPJ breast cancer · 2021Article
- Circadian clock: a regulator of the immunity in cancer.Cell communication and signaling : CCS · 2021Review
- Analysis of Mutations and Dysregulated Pathways Unravels Carcinogenic Effect and Clinical Actionability of Mutational Processes.Frontiers in cell and developmental biology · 2021Article
- Comprehensive bioinformatics analyses of APOBECs family and identification of APOBEC3D as the unfavorable prognostic biomarker in clear cell renal cell carcinoma.Journal of Cancer · 2021Article
- Identifying Drug Sensitivity Subnetworks with NETPHIX.iScience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundStudies of cancer mutations have typically focused on identifying cancer driving mutations that confer growth advantage to cancer cells. However, cancer genomes accumulate a large number of passenger somatic mutations resulting from various endogenous and exogenous causes, including normal DNA damage and repair processes or cancer-related aberrations of DNA maintenance machinery as well as mutations triggered by carcinogenic exposures. Different mutagenic processes often produce characteristic mutational patterns called mutational signatures. Identifying mutagenic processes underlying mutational signatures shaping a cancer genome is an important step towards understanding tumorigenesis.
methodsTo investigate the genetic aberrations associated with mutational signatures, we took a network-based approach considering mutational signatures as cancer phenotypes. Specifically, our analysis aims to answer the following two complementary questions: (i) what are functional pathways whose gene expression activities correlate with the strengths of mutational signatures, and (ii) are there pathways whose genetic alterations might have led to specific mutational signatures? To identify mutated pathways, we adopted a recently developed optimization method based on integer linear programming.
resultsAnalyzing a breast cancer dataset, we identified pathways associated with mutational signatures on both expression and mutation levels. Our analysis captured important differences in the etiology of the APOBEC-related signatures and the two clock-like signatures. In particular, it revealed that clustered and dispersed APOBEC mutations may be caused by different mutagenic processes. In addition, our analysis elucidated differences between two age-related signatures-one of the signatures is correlated with the expression of cell cycle genes while the other has no such correlation but shows patterns consistent with the exposure to environmental/external processes.
conclusionsThis work investigated, for the first time, a network-level association of mutational signatures and dysregulated pathways. The identified pathways and subnetworks provide novel insights into mutagenic processes that the cancer genomes might have undergone and important clues for developing personalized drug therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.